Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18243458 | 0.89 | ADRA2A (0.40) | CYSLTR2CYSLTR1 | |
| SCHEMBL18243396 | 0.87 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL10513059 | 0.83 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL18242473 | 0.82 | GABRA1 (0.44) | CYSLTR2CYSLTR1CYP3A4CYP2D6 | |
| SCHEMBL18241952 | 0.80 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL18241880 | 0.79 | CYSLTR2 (0.40) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL10979504 | 0.79 | TSHR (0.52) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL5665256 | 0.79 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL9621646 | 0.79 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL30436245 | 0.79 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | CYSLTR2 1119/4885CYSLTR1 1090/4885LIPG 3948/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | CYSLTR2 1119/4885CYSLTR1 1090/4885LIPG 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.